EMA/44693/2012

European Medicines Agency decision

P/0020/2012

of 27 January 2012

on the acceptance of a modification of an agreed paediatric investigation plan for ticagrelor (Brilique, Possia) (EMEA-000480-PIP01-08-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8409
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0020/2012

of 27 January 2012

on the acceptance of a modification of an agreed paediatric investigation plan for ticagrelor (Brilique, Possia) (EMEA-000480-PIP01-08-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/199/2009 issued on 2 October 2009, the decision P/30/2011 issued on 28 January 2011 and the decision P/239/2011 issued on 30 September 2011,

Having regard to the application submitted by AstraZeneca AB on 28 September 2011 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 December 2011, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for ticagrelor (Brilique, Possia), film-coated tablet, granules for oral suspension, oral use are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to AstraZeneca AB, Building 411A, Floor 4, S-151 85 - Sodertalje, Sweden.

Done at London, 27 January 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/593683/2011

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000480-PIP01-08-M03

Scope of the application

Active substance(s):

Ticagrelor

Invented name:

Brilique

Possia

Condition(s):

Prevention of thromboembolic events

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Granules for oral suspension

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

AstraZeneca AB

Information about the authorised medicinal product:

See Annex II

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, AstraZeneca AB submitted to the European Medicines Agency on 28 September 2011 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/199/2009 issued on 2 October 2009, the decision P/30/2011 issued on 28 January 2011 and decision P/239/2011 issued on 30 September 2011.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 12 October 2011.

Scope of the modification

Some of the agreed measures and timelines have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 9 December 2011

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: prevention of thromboembolic events

Condition / Indication: acute coronary syndrome.

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- for film-coated tablet, granules for oral suspension, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition: prevention of thromboembolic events

2.1.1. Indication(s) targeted by the PIP

Prevention of thrombosis and thromboembolic events in paediatric patients with a central venous catheter.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 0 to less than 18 years.

2.1.3. Pharmaceutical form(s)

Granules for oral suspension, oral use.

2.1.4. Studies

Area	Number of studies	Description
Quality	1	Study 1 Development of granules for oral suspension at strengths supporting appropriate dosing for oral use for paediatric patients from birth to less than 18 years.

Non-clinical	4	Study 2 Dose Range-Finding Study in Suckling Rats. Study 3 Definitive study in Suckling Rats. Study 4 Definitive Study in Weaning Rats. Study 5 Suckling rat lung function study.
Clinical	4	Study 6 Double-blind, dose-escalating study in patients aged 2 to less than 18 years of age who have a central venous catheter to determine the age-appropriate dose of ticagrelor as add on to standard-of-care treatment providing similar levels of inhibition of platelet aggregation to a 90 mg twice per day ticagrelor dose in adults. Study 7 Double-blind, dose escalating study in patients aged from birth to less than 2 years of age who have a central venous catheter (CVC) to determine the age-appropriate dose of ticagrelor providing similar levels of inhibition of platelet aggregation to a 90 mg twice per day ticagrelor dose in adults. Study 8 Randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ticagrelor added to standard of care compared with standard of care alone in patients from 6 to less than 18 years of age at risk for thrombosis due to the presence of a central venous catheter. Study 9 Randomised, double-blind, placebo-controlled study evaluating the safety of ticagrelor added to standard of care compared with standard of care alone in patients from birth to less than 8 years of age who have a central venous catheter.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2019.
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Prevention of thromboembolic events

Authorised indications:

Brilique, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).

Possia, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).

EU Number	(Invented) name	Strength	Pharmaceutical Form	Route of Administration	Packaging	Package size
EU/1/10/655/001	Brilique	90 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	60 tablets
EU/1/10/655/002	Brilique	90 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	180 tablets
EU/1/10/655/003	Brilique	90 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu), calendar pack	14 tablets
EU/1/10/655/004	Brilique	90 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu), calendar pack	56 tablets
EU/1/10/655/005	Brilique	90 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu), calendar pack	168 tablets
EU/1/10/655/006	Brilique	90 mg	Film-coated tablet	Oral use	unit dose blister (PVC/PVDC/alu)	100 x 1 tablet

EU Number	(Invented) name	Strength	Pharmaceutical Form	Route of Administration	Packaging	Package size
EU/1/10/656/001	Possia	90 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	60 tablets
EU/1/10/656/002	Possia	90 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	180 tablets
EU/1/10/656/003	Possia	90 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu), calendar pack	14 tablets
EU/1/10/656/004	Possia	90 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu), calendar pack	56 tablets
EU/1/10/656/005	Possia	90 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu), calendar pack	168 tablets
EU/1/10/656/006	Possia	90 mg	Film-coated tablet	Oral use	unit dose blister (PVC/PVDC/alu)	100 x 1 tablet